Redeye initiates coverage of Ortoma, a Swedish medtech company in early stage commercialisation with...
Redeye provides a research update following Hoylu’s Q2 2023 report.
Redeye provides a brief update on BeammWaves, after its Q2’23 report.
We have discontinued coverage of Isofol Medical. Our last published view, fair value range and estim...
Negativ organisk tillväxt och marginalpress… Med accelererande avveckling av kopparnäten såg Sverige...
Lytix has reported positive results from the first part of the phase II trial conducted by Verrica i...
Redeye comments on Remedys Q2-report. Revenue was somewhat below our estimates while EBIT was clearl...
Redeye’s initial take on BeammWaves’ Q2 2023 report was broadly in line with expectations.
Aspo’s outlook worsened this spring, and Q2 results fell below reduced estimates.
Adj. EBITA SEK 21.4m (-8% vs. ABGSCe 23.3m)Q2 numbers imply adj.
Etteplan reported Q2 results that were below our estimates.
Redeye comments on the new data regulation in India, which once again reminds investors of the regul...
Redeye updates on G5 following its Q2-results where topline was soft while results were close to our...
Redeye states that the chances of Neonode winning or settling its lawsuit against Apple and Samsung ...
Sales and adj. EBIT a tad weaker, but FCF strongerWe cut EBIT but raise FCF on lower capexShare trad...
Redeye updates its estimates and valuation following Freemelt’s Q2 report, which came in somewhat be...
Q2 adjusted EBITA fell slightly short of Refinitiv consensus expectations despite solid top-line gro...
Boreo reported Q2 2023 adjusted EBIT excluding PPA of EUR 2.
Redeye maintains its positive view on Transtema despite lowering its Base Case and forecasts.
Q2 2023 results were a bit weaker than consensus expected.
